Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs

Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of safe, effective weight loss. As demand in the U.S. reached a fever pitch, Novo faced opportunities and challenges. The case covers the markets in which Novo could expand, the manufacturing shortfalls it faced, the competition that was expected to arise, and the moral issues that came with selling a product that affected so many people worldwide.